|
1
|
Murphy BR, Prince GA, Collins PL, Van Wyke
Coelingh K, Olmsted RA, et al: Current approaches to the
development of vaccines effective against parainfluenza and
respiratory syncytial viruses. Virus Res. 11:1–15. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kim HW, Canchola JG, Brandt CD, Pyles G,
Chanock RM, et al: Respiratory syncytial virus disease in infants
despite prior administration of antigenic inactivated vaccine. Am J
Epidemiol. 89:422–434. 1969.PubMed/NCBI
|
|
3
|
Collins PL and Graham BS: Viral and host
factors in human respiratory syncytial virus pathogenesis. J Virol.
82:2040–2055. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chin J, Magoffin RL, Shearer LA, Schieble
JH and Lennette EH: Field evaluation of a respiratory syncytial
virus vaccine and a trivalent parainfluenza virus vaccine in a
pediatric population. Am J Epidemiol. 89:449–463. 1969.PubMed/NCBI
|
|
5
|
Fulginiti VA, Eller JJ, Sieber OF, Joyner
JW, Minamitani M and Meiklejohn G: Respiratory virus immunization.
I. A field trial of two inactivated respiratory virus vaccines; an
aqueous trivalent parainfluenza virus vaccine and an
alum-precipitated respiratory syncytial virus vaccine. Am J
Epidemiol. 89:435–448. 1969.
|
|
6
|
Garofalo RP, Kolli D and Casola A:
Respiratory syncytial virus infection: mechanisms of redox control
and novel therapeutic opportunities. Antioxid Redox Signal.
18:186–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Becker S, Soukup J and Yankaskas JR:
Respiratory syncytial virus infection of human primary nasal and
bronchial epithelial cell cultures and bronchoalveolar macrophages.
Am J Respir Cell Mol Biol. 6:369–374. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hong CE and Lyu SY: Anti-inflammatory and
anti-oxidative effects of Korean red ginseng extract in human
keratinocytes. Immune Netw. 11:42–49. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Culley FJ, Pennycook AM, Tregoning JS,
Hussell T and Openshaw PJ: Differential chemokine expression
following respiratory virus infection reflects Th1- or Th2-biased
immunopathology. J Virol. 80:4521–4527. 2006. View Article : Google Scholar
|
|
10
|
Jiang Z, Kunimoto M and Patel JA:
Autocrine regulation and experimental modulation of interleukin-6
expression by human pulmonary epithelial cells infected with
respiratory syncytial virus. J Virol. 72:2496–2499. 1998.PubMed/NCBI
|
|
11
|
Hammad H and Lambrecht BN: Dendritic cells
and epithelial cells: linking innate and adaptive immunity in
asthma. Nat Rev Immunol. 8:193–204. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kwok HH, Ng WY, Yang MS, Mak NK, Wong RN
and Yue PY: The ginsenoside protopanaxatriol protects endothelial
cells from hydrogen peroxide-induced cell injury and cell death by
modulating intracellular redox status. Free Radic Biol Med.
48:437–445. 2010. View Article : Google Scholar
|
|
13
|
Chan LY, Kwok HH, Chan RW, Peiris MJ, Mak
NK, et al: Dual functions of ginsenosides in protecting human
endothelial cells against influenza H9N2-induced inflammation and
apoptosis. J Ethnopharmacol. 137:1542–1546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moore ML, Chi MH, Luongo C, Lukacs NW,
Polosukhin VV, et al: A chimeric A2 strain of respiratory syncytial
virus (RSV) with the fusion protein of RSV strain line 19 exhibits
enhanced viral load, mucus, and airway dysfunction. J Virol.
83:4185–4194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Quan FS, Kim Y, Lee S, Yi H, Kang SM, et
al: Viruslike particle vaccine induces protection against
respiratory syncytial virus infection in mice. J Infect Dis.
204:987–995. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Panuska JR, Merolla R, Rebert NA, Hoffmann
SP, Tsivitse P, et al: Respiratory syncytial virus induces
interleukin-10 by human alveolar macrophages. Suppression of early
cytokine production and implications for incomplete immunity. J
Clin Invest. 96:2445–2453. 1995. View Article : Google Scholar
|
|
17
|
Arnold R, König B, Galatti H, Werchau H
and König W: Cytokine (IL-8, IL-6, TNF-alpha) and soluble TNF
receptor-I release from human peripheral blood mononuclear cells
after respiratory syncytial virus infection. Immunology.
85:364–372. 1995.
|
|
18
|
Zhang Y, Luxon BA, Casola A, Garofalo RP,
Jamaluddin M and Brasier AR: Expression of respiratory syncytial
virus-induced chemokine gene networks in lower airway epithelial
cells revealed by cDNA microarrays. J Virol. 75:9044–9058. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee DC and Lau AS: Effects of Panax
ginseng on tumor necrosis factor-α-mediated inflammation: a
mini-review. Molecules. 16:2802–2816. 2011.
|
|
20
|
Legg JP, Hussain IR, Warner JA, Johnston
SL and Warner JO: Type 1 and type 2 cytokine imbalance in acute
respiratory syncytial virus bronchiolitis. Am J Respir Crit Care
Med. 168:633–639. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsuse H, Hirose H, Tsuchida T, Fukahori
S, Fukushima C, et al: Effects of respiratory syncytial virus
infection on dendritic cells and cysteinyl leukotrienes in lung
tissues of a murine model of asthma. Allergol Int. 56:165–169.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song JM, Hossain J, Yoo DG, Lipatov AS,
Davis CT, et al: Protective immunity against H5N1 influenza virus
by a single dose vaccination with virus-like particles. Virology.
405:165–175. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song JM, Van Rooijen N, Bozja J, Compans
RW and Kang SM: Vaccination inducing broad and improved cross
protection against multiple subtypes of influenza A virus. Proc
Natl Acad Sci USA. 108:757–761. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Attele AS, Wu JA and Yuan CS: Ginseng
pharmacology: multiple constituents and multiple actions. Biochem
Pharmacol. 58:1685–1693. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jie YH, Cammisuli S and Baggiolini M:
Immunomodulatory effects of Panax Ginseng C.A. Meyer in the
mouse. Agents Actions. 15:386–391. 1984.
|
|
26
|
Pulendran B: Modulating vaccine responses
with dendritic cells and Toll-like receptors. Immunol Rev.
199:227–250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Panuska JR, Midulla F, Cirino NM, Villani
A, Gilbert IA, et al: Virus-induced alterations in macrophage
production of tumor necrosis factor and prostaglandin E2. Am J
Physiol. 259:L396–L402. 1990.PubMed/NCBI
|
|
28
|
Zeng R, Li C, Li N, Wei L and Cui Y: The
role of cytokines and chemokines in severe respiratory syncytial
virus infection and subsequent asthma. Cytokine. 53:1–7. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cormier SA, You D and Honnegowda S: The
use of a neonatal mouse model to study respiratory syncytial virus
infections. Expert Rev Anti Infect Ther. 8:1371–1380. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mata M, Morcillo E, Gimeno C and Cortijo
J: N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and
pro-inflammatory mediators in alveolar type II epithelial cells
infected with influenza virus A and B and with respiratory
syncytial virus (RSV). Biochem Pharmacol. 82:548–555. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Watanabe W, Shimizu T, Sawamura R, Hino A,
Konno K, et al: Effects of tetrabromobisphenol A, a brominated
flame retardant, on the immune response to respiratory syncytial
virus infection in mice. Int Immunopharmacol. 10:393–397. 2010.
View Article : Google Scholar : PubMed/NCBI
|
